OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
"HOT PROMO DARI P0KERV1TA untuk para member kami :
* B0nus Referral 20% Seumur Hidup
* Bonus Hariaan Hingga 3juta
* Bonus Bulanan Hadiah Spesial untuk member yang bermain selama 1 bulan penuh
* Bonus Turn0ver 0,5%
* NO ROBOT & ADMIN
* 100% Fair Play Member Vs Member
* Proses Withdraw & Deposit Tercepat
* Customer Service yang baik dan ramah
Contact Us Person :
? LIVECHAT POKERV1TA
? WA: 082312256064
? BBM : D88B0154"
